LifeScan Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
LifeScan Inc. - overview
Established
1981
Location
-, PA, US
Primary Industry
Medical Devices & Equipment
About
LifeScan Inc. is a US-based manufacturer specializing in diabetes management products, particularly known for its OneTouch® brand that provides innovative glucose monitoring solutions to enhance patient care. LifeScan Inc. is a manufacturer of diabetes management products that was founded in 1981.
The company was acquired by Platinum Equity in a DEAL worth USD 2. 1 billion from Johnson & Johnson, with the acquisition completed in October 2018. The company has undergone significant ownership changes but continues to focus on diabetes care. Julia Hango, Medison Simbolon, and Nikos Vogiatzis are credited as the founders of LifeScan.
The current CEO is Patrick Czompo, who leads the company in its operations. LifeScan is known for its OneTouch® product line, which includes the OneTouch Verio Flex® blood glucose meter and the OneTouch Reveal® mobile application. These products utilize advanced ColorSure® technology to provide users with clear insights into their glucose levels, aiding in effective diabetes management. LifeScan caters to a wide customer base, including patients, healthcare providers, and caregivers, ensuring extensive distribution of its products across North America, Europe, and Asia.
In 2017, LifeScan generated revenue of USD 1. 50 bn through a combination of sales of glucose meters, test strips, and digital health solutions. The company engages in both direct-to-consumer sales and partnerships with healthcare providers and retailers, facilitating access to its diabetes management products. LifeScan's recent acquisition by Platinum Equity in October 2018 for USD 2.
1 billion marks a pivotal moment for the company. While specific upcoming product releases have not been detailed, the infusion of capital is expected to enhance LifeScan's product offerings and potentially expand into new geographic markets. The company aims to leverage this funding to bolster its existing operations and develop innovative solutions in diabetes management.
Current Investors
Platinum Equity
Primary Industry
Medical Devices & Equipment
Sub Industries
Healthcare IT, Monitoring Equipment, Medical Software
Website
www.lifescan.com/
Verticals
HealthTech
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
LifeScan Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | LifeScan Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.